Key regions: Brazil, India, Australia, United States, United Kingdom
Cambodia, a country located in Southeast Asia, has seen a steady growth in its Antiviral Drugs market in recent years.
Customer preferences: Cambodia's Antiviral Drugs market is primarily driven by the demand for drugs to treat viral infections such as HIV/AIDS, hepatitis B and C, and influenza. The market is dominated by generic drugs due to their affordability and accessibility.
Trends in the market: The Antiviral Drugs market in Cambodia has witnessed a significant increase in demand due to the rising prevalence of viral infections. The government's efforts to increase awareness about HIV/AIDS and other viral infections have also contributed to the growth of the market. Additionally, the increasing availability of Antiviral Drugs in the country has made it easier for patients to access treatment.
Local special circumstances: Cambodia has a high prevalence of HIV/AIDS, with an estimated 73,000 people living with the disease in 2020. The government has implemented several initiatives to combat the spread of the disease, including increasing access to Antiviral Drugs. Additionally, the country has a high incidence of hepatitis B and C, which has further fueled the demand for Antiviral Drugs.
Underlying macroeconomic factors: Cambodia's Antiviral Drugs market is also influenced by macroeconomic factors such as the country's GDP growth, healthcare expenditure, and government policies. The country's GDP has been growing steadily in recent years, which has led to an increase in healthcare expenditure. The government has also implemented policies to improve access to healthcare services, including Antiviral Drugs. However, the market is still facing challenges such as a lack of healthcare infrastructure and limited access to healthcare services in rural areas.In conclusion, the Antiviral Drugs market in Cambodia is expected to continue growing in the coming years due to the rising prevalence of viral infections and the government's efforts to increase access to healthcare services. However, the market still faces challenges such as a lack of healthcare infrastructure and limited access to healthcare services in rural areas.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
